These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23116144)

  • 1. Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery.
    Song Y; Zhan P; Li X; Rai D; De Clercq E; Liu X
    Curr Med Chem; 2013 Feb; 20(6):815-32. PubMed ID: 23116144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 drug discovery: targeting folded RNA structures with branched peptides.
    Wynn JE; Santos WL
    Org Biomol Chem; 2015 Jun; 13(21):5848-58. PubMed ID: 25958855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
    Flores A; Quesada E
    Curr Med Chem; 2013 Feb; 20(6):751-71. PubMed ID: 23278399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular strategies to design an escape-proof antiviral therapy.
    Berkhout B; Sanders RW
    Antiviral Res; 2011 Oct; 92(1):7-14. PubMed ID: 21513746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.
    Kang D; Song Y; Chen W; Zhan P; Liu X
    Mol Biosyst; 2014 Aug; 10(8):1998-2022. PubMed ID: 24841339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic routes and structure-activity relationships (SAR) of anti-HIV agents: A key review.
    Huang YM; Alharbi NS; Sun B; Shantharam CS; Rakesh KP; Qin HL
    Eur J Med Chem; 2019 Nov; 181():111566. PubMed ID: 31401538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking HIV entry.
    Buzko OV; Shokat KM
    Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.
    Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational restriction: an effective tactic in 'follow-on'-based drug discovery.
    Fang Z; Song Y; Zhan P; Zhang Q; Liu X
    Future Med Chem; 2014 May; 6(8):885-901. PubMed ID: 24962281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2).
    Huang B; Zhou Z; Kang D; Li W; Chen Z; Zhan P; Liu X
    Expert Opin Ther Pat; 2017 Jan; 27(1):9-15. PubMed ID: 27855563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of 1-(thiophen-2-yl)-9H-pyrido[3,4-b]indole Derivatives as Anti-HIV-1 Agents.
    Ashok P; Lu CL; Chander S; Zheng YT; Murugesan S
    Chem Biol Drug Des; 2015 Jun; 85(6):722-8. PubMed ID: 25328020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
    Berinyuy E; Soliman ME
    J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.
    Zhang L; Guo J; Liu X; Liu H; De Clercq E; Pannecouque C; Liu X
    Chem Biol Drug Des; 2015 Sep; 86(3):333-43. PubMed ID: 25511999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
    Andrianov AM; Anishchenko IV; Tuzikov AV
    J Chem Inf Model; 2011 Oct; 51(10):2760-7. PubMed ID: 21888425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.